Thiel Capital

Inflection Points operates a specialized employment and training platform focused on the bitcoin and cryptocurrency sectors. The company offers services that facilitate connections between employers and candidates, enabling businesses to recruit talent and individuals to discover job opportunities within the growing crypto industry. Additionally, Inflection Points provides training programs aimed at enhancing skills relevant to bitcoin and cryptocurrency, further supporting workforce development in this dynamic field.

Regent is a maritime mobility company founded in 2020 and headquartered in Winchester, Massachusetts. The company specializes in developing all-electric sea gliders designed to provide fast, safe, and cost-effective coastal transportation. These innovative machines fly just above the water's surface, serving as a replacement for traditional ferries and short-haul aircraft on coastal routes. By combining the high speed of an airplane with the lower operating costs of a boat, Regent aims to enhance local and regional transportation options between coastal cities, improving accessibility and efficiency for its customers.

Mynaric AG specializes in laser communication solutions for high-speed and long-distance wireless data transmission among moving objects. Founded in 2009 and headquartered in Gilching, Germany, the company offers a range of products, including air-to-ground, air-to-air, and space terminals, as well as optical ground stations. Mynaric's technology aims to address the growing demand for fast and reliable network connectivity beyond traditional ground-based infrastructure, facilitating an "internet above the clouds." This expansion is essential for connecting underserved populations and linking numerous devices globally. By providing advanced laser communication products, Mynaric plays a crucial role in developing the necessary data highways for telecommunication networks in the air and space domains.

Ex-human is building a Digital Human Platform that allows anyone to create fully customizable interactive AI Humans. We provide Digital Humans as a Service supporting hyper-realistic open-domain conversations. Our customers are companies in the dating, gaming, chatbot, and VR industries who use our AI solution to boost users engagement.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

Bullish Global is a new blockchain-based cryptocurrency exchange designed to combine the performance, user privacy, and compliance offered by central order book technology with the vertically integrated user benefits of decentralized finance (DeFi) market architecture.

Regent is a maritime mobility company founded in 2020 and headquartered in Winchester, Massachusetts. The company specializes in developing all-electric sea gliders designed to provide fast, safe, and cost-effective coastal transportation. These innovative machines fly just above the water's surface, serving as a replacement for traditional ferries and short-haul aircraft on coastal routes. By combining the high speed of an airplane with the lower operating costs of a boat, Regent aims to enhance local and regional transportation options between coastal cities, improving accessibility and efficiency for its customers.

Angiex is a biotechnology company focused on developing vascular-targeted biotherapeutics for cancer treatment. Founded by leading scientists, the company specializes in antibody-drug conjugate therapies that address key aspects of endothelial biology, particularly angiogenesis. Angiex's lead product utilizes a novel approach to deliver therapeutic agents directly to the nucleus of tumor cells and to the activated endothelium of tumors and inflamed vessels. This innovative method aims to enhance the efficacy of treatments for various solid tumors, including pancreatic, lung, liver cancers, and glioblastoma multiforme. With intellectual property originating from Beth Israel Deaconess Medical Center, Angiex operates out of LabCentral in Cambridge, positioning itself at the forefront of cancer therapeutics.

ATAI Life Sciences AG is a clinical-stage biopharmaceutical company headquartered in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative treatments for mental health disorders, addressing significant unmet medical needs. ATAI employs a decentralized, technology-driven platform model to accelerate the development of therapies. Its diverse portfolio includes product candidates such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and GRX-917 (Deuterated etifoxine), among others. By pooling expertise and resources, ATAI aims to create impactful, evidence-based therapies that can transform mental health treatment. The company operates primarily in Germany and the United States.

Rational Vaccines preclinical stage herpes vaccine development company actively working to improve lives with the hope of revolutionizing the treatment, prevention, and diagnosis of herpes and herpes-related diseases worldwide. Rational Vaccines was founded in 2015 and headquartered in Cambridge, Massachusetts.

ATAI Life Sciences AG is a clinical-stage biopharmaceutical company headquartered in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative treatments for mental health disorders, addressing significant unmet medical needs. ATAI employs a decentralized, technology-driven platform model to accelerate the development of therapies. Its diverse portfolio includes product candidates such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and GRX-917 (Deuterated etifoxine), among others. By pooling expertise and resources, ATAI aims to create impactful, evidence-based therapies that can transform mental health treatment. The company operates primarily in Germany and the United States.

Ready.net is a software development company that specializes in creating business and operational tools for internet service providers (ISPs). Founded in 2020 and headquartered in San Francisco, California, the company offers a product called Back Office Secret Sauce (BOSS). This innovative software enables ISP subscribers to manage their networks independently, facilitating tasks such as upgrading service plans, selecting additional services, paying bills online, and receiving assistance through a chatbot. Ready.net aims to enhance the operational efficiency of local ISPs while providing a user-friendly experience for their customers.

ATAI Life Sciences AG is a clinical-stage biopharmaceutical company headquartered in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative treatments for mental health disorders, addressing significant unmet medical needs. ATAI employs a decentralized, technology-driven platform model to accelerate the development of therapies. Its diverse portfolio includes product candidates such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and GRX-917 (Deuterated etifoxine), among others. By pooling expertise and resources, ATAI aims to create impactful, evidence-based therapies that can transform mental health treatment. The company operates primarily in Germany and the United States.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

Advano, operating under NanoStar, Inc., is a New Orleans-based company specializing in silicon nanotechnology. Founded in 2014, Advano develops and produces functionalized silicon nanoparticles and quantum dots for various applications. Notably, its products enhance the energy density of lithium-ion batteries by 30-40%, making them suitable for electric vehicles, consumer electronics, and IoT devices, all without compromising battery life or increasing costs. Additionally, Advano's technology is applied in CO2 carbon capture, super hydrophobic coatings, and printable electronics, serving industries such as telecommunications.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

EnClear Therapies, Inc. is a life sciences company based in Newburyport, Massachusetts, focused on developing device-based therapies for neurodegenerative diseases. The company specializes in the delivery and monitoring of cerebrospinal fluid (CSF) and has created a proprietary therapeutic platform aimed at removing toxic proteins from the CSF. EnClear's products are primarily designed to improve the lives of patients suffering from conditions such as Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP). By providing innovative solutions in the treatment of these neurological diseases, EnClear Therapies aims to help halt disease progression and extend patient lifespans.

SPARK Neuro is a neuroscience company that revolutionizes the of audience engagement in advertising and entertainment. Instead of relying on traditional, biased research methods, SPARK Neuro goes right to the source, measuring brain and nervous system activity. SPARK Neuro quantifies attention and emotional levels with second-by-second precision. Founded in 2016, SPARK’s research is trusted by major brands including GM, Clorox, Toyota, Procter & Gamble, NBC, Universal Pictures, Telemundo, and Netflix.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.

Terminal Inc. specializes in recruitment services and the development and management of workspaces for technology companies. Founded in 2017 and headquartered in San Francisco, California, with additional offices in Canada and Mexico, the company connects elite engineers with high-growth firms across emerging tech hubs worldwide. Terminal provides comprehensive operational support, including human resources, benefits, payroll, and legal administration, enabling companies to operate efficiently in new markets. By fostering communities of top technologists, Terminal helps organizations tackle complex challenges in various software development areas, such as data science, DevOps, and augmented/virtual reality. The firm exclusively partners with technology companies backed by prominent venture capitalists, ensuring they maintain competitive advantages and access to global tech leaders.

Invicta Medical, Inc. is a medical technology company based in Portola Valley, California, focused on developing a wearable device designed for the treatment of sleep apnea and snoring. Founded in 2013, the company’s innovative device detects instances of disturbed breathing and employs electrical stimulation to provide therapeutic intervention. Invicta Medical aims to improve the quality of life for individuals suffering from sleep-related disorders through its pioneering approach to treatment.

Beijing Immunochina Pharmaceuticals Co., Ltd. is a clinical-stage biotechnology company focused on the research and development of chimeric antigen receptor (CAR) T-cell therapies and a lentiviral vector manufacturing platform aimed at treating malignant tumors. The company's pipeline includes therapies targeting CD19, which is prevalent in various B-lineage malignancies such as acute B-cell lymphoblastic leukemia and non-Hodgkin's lymphoma; B cell maturation antigen (BCMA) for multiple myeloma; and CD123, associated with leukemia blasts and stem cells. Additionally, Immunochina is conducting clinical studies on CAR-T cells for relapsed and refractory non-Hodgkin's lymphoma. Founded in 2015 and based in Beijing, the company also engages in the production of cell injections, cell therapy drugs, and offers services related to medical technology development and clinical research.

3T Biosciences, Inc. is an immunotherapy company established in 2017 and based in Menlo Park, California. The company focuses on developing innovative treatments for cancer and other T-cell-mediated diseases by utilizing synthetic biology and machine learning technologies. Its approach involves discovering novel targets for drug development, which aims to enhance the effectiveness of cancer therapies. Through its research and development efforts, 3T Biosciences is committed to providing healthcare professionals with advanced treatment options for patients facing cancer-related illnesses.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.

Angiex is a biotechnology company focused on developing vascular-targeted biotherapeutics for cancer treatment. Founded by leading scientists, the company specializes in antibody-drug conjugate therapies that address key aspects of endothelial biology, particularly angiogenesis. Angiex's lead product utilizes a novel approach to deliver therapeutic agents directly to the nucleus of tumor cells and to the activated endothelium of tumors and inflamed vessels. This innovative method aims to enhance the efficacy of treatments for various solid tumors, including pancreatic, lung, liver cancers, and glioblastoma multiforme. With intellectual property originating from Beth Israel Deaconess Medical Center, Angiex operates out of LabCentral in Cambridge, positioning itself at the forefront of cancer therapeutics.

Invicta Medical, Inc. is a medical technology company based in Portola Valley, California, focused on developing a wearable device designed for the treatment of sleep apnea and snoring. Founded in 2013, the company’s innovative device detects instances of disturbed breathing and employs electrical stimulation to provide therapeutic intervention. Invicta Medical aims to improve the quality of life for individuals suffering from sleep-related disorders through its pioneering approach to treatment.